[May-Hegglin anomaly: past and present--novel diagnostic test and new concept of the disease]
1Laboratory of Molecular Diagnosis, Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya 460-0001, Japan. kunishis@nnh.hosp.go.jp
May-Hegglin anomaly(MHA) is the prototype of the autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies/MYH9 disorders that result from mutations in MYH9, the gene for nonmuscle myosin heavy chain-IIA(NMMHC-IIA). Others include Sebastian(SBS), Fechtner(FTNS), and Epstein (EPS) syndromes. Clear phenotype-genotype relationships have not been found; however, patients with an MYH9 head domain mutation tend to develop Alport manifestation more frequently than those with a rod mutation. The hallmark of MYH9 disorders is the presence of granulocyte inclusion bodies. We revealed that mutant NMMHC-IIA was present and sequestered only in inclusion bodies within neutrophils, diffusely distributed throughout lymphocyte cytoplasm, sparsely localized on a diffuse cytoplasmic background in monocytes, and uniformly distributed at diminished levels only in large platelets. We showed the differential expression of mutant NMMHC-IIA, and postulated that cell-specific regulation mechanisms function in MYH9 disorders.
May-Hegglin anomaly(MHA) is the prototype of the autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies/MYH9 disorders that result from mutations in MYH9, the gene for nonmuscle myosin heavy chain-IIA(NMMHC-IIA). Others include Sebastian(SBS), Fechtner(FTNS), and Epstein (EPS) syndromes. Clear phenotype-genotype relationships have not been found; however, patients with an MYH9 head domain mutation tend to develop Alport manifestation more frequently than those with a rod mutation. The hallmark of MYH9 disorders is the presence of granulocyte inclusion bodies. We revealed that mutant NMMHC-IIA was present and sequestered only in inclusion bodies within neutrophils, diffusely distributed throughout lymphocyte cytoplasm, sparsely localized on a diffuse cytoplasmic background in monocytes, and uniformly distributed at diminished levels only in large platelets. We showed the differential expression of mutant NMMHC-IIA, and postulated that cell-specific regulation mechanisms function in MYH9 disorders.
Related Concept Videos
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Mitral Stenosis II: Clinical features and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Huntington Disease l: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...


